title: Heart failure: its progression and its therapy.
abstract: The complex pathology that leads to heart failure has hampered the search for optimal therapy. Even so, ACE inhibitors have become a cornerstone of treatment. After an acute MI, the goal of ACE inhibition is to limit LV remodeling and progression to ischemic cardiomyopathy and congestive failure. In advanced failure, the goal is to reverse peripheral vascular changes and ameliorate symptoms.
authors.affiliation: Division of Cardiology, Albert Einstein College of Medicine, Bronx, N.Y.
authors.forename: E H
authors.initials: EH
authors.lastname: Sonnenblick
authors.forename: T H
authors.initials: TH
authors.lastname: LeJemtel
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy / Q000473:pathology*; D002311:Cardiomyopathy, Dilated / Q000503:physiopathology; D002316:Cardiotonic Agents / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D015425:Myocardial Reperfusion; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents